Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Traffic & App Usage Insights

Discover domain traffic and app usage trends for companies and their competitors.

TENX

Tenax Therapeutics Inc

Oct 08 • 04:00PM ET

3.28

Dollar change -0.04
Percentage change -1.23	%

Healthcare • Biotechnology • USA • NASD

Held by: VXF DFSU

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-22.37	Insider Own	12.50%	Shs Outstand	3.41M	Perf Week	-3.53%
Market Cap	11.18M	Forward P/E	-	EPS next Y	-4.61	Insider Trans	0.00%	Shs Float	2.98M	Perf Month	-10.63%
Income	-12.57M	PEG	-	EPS next Q	-1.33	Inst Own	31.09%	Short Float	1.69%	Perf Quarter	-1.50%
Sales	0.00M	P/S	-	EPS this Y	79.20%	Inst Trans	-	Short Ratio	0.10	Perf Half Y	-16.33%
Book/sh	4.53	P/B	0.72	EPS next Y	28.58%	ROA	-101.95%	Short Interest	0.05M	Perf Year	-85.14%
Cash/sh	2.75	P/C	1.19	EPS next 5Y	-	ROE	-113.79%	52W Range	2.77 - 61.20	Perf YTD	-85.07%
Dividend Est.	-	P/FCF	-	EPS past 5Y	70.74%	ROI	-141.64%	52W High	-94.64%	Beta	2.19
Dividend TTM	-	Quick Ratio	6.10	Sales past 5Y	0.00%	Gross Margin	-	52W Low	18.41%	ATR (14)	0.22
Dividend Ex-Date	-	Current Ratio	6.10	EPS Y/Y TTM	92.08%	Oper. Margin	0.00%	RSI (14)	35.42	Volatility	5.64% 6.21%
Employees	5	Debt/Eq	0.03	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	30.00
Option/Short	No / Yes	LT Debt/Eq	0.00	EPS Q/Q	54.37%	Payout	-	Rel Volume	0.03	Prev Close	3.32
Sales Surprise	-	EPS Surprise	7.81%	Sales Q/Q	-	Earnings	Aug 13 AMC	Avg Volume	497.79K	Price	3.28
SMA20	-6.78%	SMA50	-11.69%	SMA200	-39.60%	Trades		Volume	15,357	Change	-1.23%

Date	Action	Analyst	Rating Change	Price Target Change
Sep-30-24	Initiated	William Blair	Outperform
May-18-17	Upgrade	Ladenburg Thalmann	Neutral → Buy
Dec-16-14	Initiated	MLV & Co	Buy	$7
Nov-18-14	Initiated	WallachBeth	Buy	$12

Aug-13-24 04:37PM	Tenax Therapeutics: Q2 Earnings Snapshot (Associated Press Finance) +11.63%
04:05PM	Tenax Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-12-24 08:00AM	Tenax Therapeutics Announces Closing of $100 Million Private Placement and Plans to Accelerate the Oral Levosimendan Phase 3 Program (GlobeNewswire) -10.86%
Aug-06-24 07:13AM	Tenax Therapeutics Announces Oversubscribed $100 Million Private Placement (GlobeNewswire) +28.77%
May-14-24 01:53PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q1 2024 (InvestorPlace)
08:10AM	Loading…
08:10AM	Tenax Therapeutics: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Tenax Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update (GlobeNewswire)
Apr-30-24 07:30AM	Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +6.27%
Apr-09-24 08:30AM	Tenax Therapeutics to Host KOL Event: LEVEL Setting: the Scientific Rationale for Levosimendan as a Potential First Treatment for PH-HFpEF, and the Ongoing Phase 3 LEVEL Study (GlobeNewswire)
Mar-28-24 09:54PM	TENX Stock Earnings: Tenax Therapeutics Misses EPS for Q4 2023 (InvestorPlace) +9.56% -9.91%
08:30AM	Tenax Therapeutics Provides Business and Clinical Development Updates with Full Year 2023 Financial Results (GlobeNewswire)
Mar-12-24 08:30AM	Tenax Therapeutics to Present at the 36th Annual Roth Conference (GlobeNewswire)
Feb-29-24 09:00AM	Tenax Therapeutics Announces Oral Presentation of Levosimendan for the Treatment of PH-HFpEF at THT 2024 (GlobeNewswire) +10.87%
Feb-20-24 08:30AM	Tenax Therapeutics Announces Global License Amendment that Significantly Expands Rights to Levosimendan (GlobeNewswire)
Feb-08-24 08:53AM	Why Is Tenax Therapeutics (TENX) Stock Down 64% Today? (InvestorPlace) -64.45%
08:16AM	Loading…
08:16AM	Tenax Therapeutics Announces Pricing of Approximately $9 Million Public Offering (GlobeNewswire)
Feb-07-24 08:01PM	Tenax Therapeutics Enrolls First Patient in Phase 3 LEVEL Study Evaluating TNX-103 (Oral Levosimendan) for the Treatment of Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +24.54%
Feb-06-24 08:30AM	Tenax Therapeutics Announces USPTO Grants Notice of Allowance for U.S. Patent Application, Significantly Broadening IP Protection for Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +31.31%
Dec-29-23 08:30AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire) -16.79%
Nov-17-23 08:30AM	Tenax Therapeutics Announces Professor Javed Butler, M.D., M.P.H, M.B.A., joins PH-HFpEF Scientific Advisory Board (GlobeNewswire) -9.21%
Nov-14-23 05:05AM	Tenax Therapeutics: Q3 Earnings Snapshot (Associated Press Finance) -18.55%
Nov-13-23 03:22PM	Why Is Tenax Therapeutics (TENX) Stock Up 300% Today? (InvestorPlace) +297.44%
08:30AM	Tenax Therapeutics Announces FDA Clearance of IND for TNX-103 (oral levosimendan) for the Treatment of Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF), Initiation of Phase 3 sites expected 2023 (GlobeNewswire)
Aug-28-23 08:20AM	TENX: Second Quarter Results (Zacks) -5.96%
Aug-25-23 07:20AM	7 F-Rated Biotech Stocks You Shouldnt Touch With a 10-Foot Pole (InvestorPlace)
Jul-19-23 08:30AM	Tenax Therapeutics Issued U.S. Patent for Oral Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +10.40%
Jun-23-23 06:24AM	TENX: Notice of Allowance Increases Confidence (Zacks Small Cap Research) +9.19%
May-31-23 08:54AM	Tenax Therapeutics Achieves Major Milestone as USPTO Grants Notice of Allowance for U.S. Patent Application Covering Use of Oral Levosimendan (TNX-103) in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) +13.31%
May-22-23 06:44AM	TENX: Prioritizing Levosimendan (Zacks Small Cap Research) +5.71%
Apr-21-23 03:59PM	10 Stocks Targeted By Short Sellers Recently (Insider Monkey)
02:50PM	Loading…
Apr-12-23 02:50PM	Tenax Therapeutics Prioritizes Development Of TNX-103 For Heart Failure (Benzinga)
08:45AM	Tenax Therapeutics Provides 2023 Business Update (GlobeNewswire)
Apr-05-23 05:49AM	TENX: Patents Guide the Way (Zacks Small Cap Research) -7.89%
Mar-22-23 08:45AM	Tenax Announces Issuance of U.S. Patent Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -5.36%
Feb-17-23 07:05AM	Analysts Are Optimistic We'll See A Profit From Tenax Therapeutics, Inc. (NASDAQ:TENX) (Simply Wall St.)
Feb-15-23 08:05AM	TENX: New Funding Puts Wind in the Sails (Zacks Small Cap Research)
Feb-07-23 12:10PM	Triangle pharma raising millions amid uncertain future (American City Business Journals) -8.02%
Feb-03-23 08:19AM	Tenax Therapeutics Announces Pricing of Approximately $15.6 Million Public Offering (GlobeNewswire) -20.81%
Feb-02-23 10:43AM	Why Tenax Therapeutics Shares Are Gaining Today? (Benzinga) +30.77%
Feb-01-23 04:31PM	Tenax Granted Notice of Allowance for U.S. Patent Application Covering Use of IV Levosimendan in Pulmonary Hypertension with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire) -20.28%
Jan-04-23 08:00AM	Tenax Therapeutics Announces Reverse Stock Split (GlobeNewswire)
Nov-03-22 07:16AM	TENX: Agility Required to Unlock Considerable Upside (Zacks Small Cap Research) -20.03%
Oct-10-22 08:30AM	Positive Data Presented at HFSA Annual Meeting Demonstrate Effects of Oral Levosimendan in Patients with Pulmonary Hypertension and Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (GlobeNewswire)
Sep-15-22 09:29AM	Tenax Therapeutics Stock Jumps On Strategic Alternative Review (Benzinga) +11.25%
08:30AM	Tenax Therapeutics Announces the Evaluation of Strategic Alternatives (GlobeNewswire)
Aug-28-22 09:23AM	Loss-Making Tenax Therapeutics, Inc. (NASDAQ:TENX) Expected To Breakeven In The Medium-Term (Simply Wall St.)
Aug-23-22 05:58AM	TENX: The Pressures On: Awaiting Phase 3 Start (Zacks Small Cap Research)
Jul-01-22 07:52AM	Chapel Hill company given extension to regain Nasdaq compliance (American City Business Journals) +6.07%
May-25-22 08:30AM	Tenax Therapeutics Hosting Key Opinion Leader Webinar on TNX-201: A Potential Treatment for Pulmonary Arterial Hypertension (PAH) (Business Wire)
May-23-22 08:30AM	Tenax Therapeutics Announces Successful Comparative Pharmacokinetic Study of TNX-201 for the Treatment of Pulmonary Arterial Hypertension (Business Wire) +6.92%
May-19-22 08:18AM	TENX: 1Q:22 Financial and Operational Review (Zacks Small Cap Research)
May-18-22 08:30AM	Tenax Therapeutics Announces $8 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Business Wire) +7.27%
Apr-01-22 09:25AM	TENX: 2021 Financial and Operational Review (Zacks Small Cap Research)
Mar-31-22 08:30AM	Tenax Therapeutics Reports Fiscal Year 2021 Results and Provides Business Update (Business Wire)
Mar-30-22 05:00PM	Tenax Therapeutics Announces Two Presentations at Upcoming American College of Cardiology Scientific Sessions (Business Wire)
Jan-31-22 04:10PM	Tenax Therapeutics Appoints Robyn Hunter to the Board of Directors (GlobeNewswire)
Jan-12-22 08:30AM	Tenax Therapeutics Granted U.S. Patent for the Subcutaneous Use of Levosimendan (TNX-102) (GlobeNewswire)
Jan-05-22 11:48AM	TENX: TNX-103 & TNX-201 Near Ready for Phase III (Zacks Small Cap Research)
Jan-04-22 08:30AM	Tenax Therapeutics Provides Update on TNX-102, TNX-103 and TNX-201 Clinical Programs (GlobeNewswire) -9.01%
Nov-18-21 11:54AM	TENX: Imatinib IND Cleared & PK Study Near End (Zacks Small Cap Research) -5.22%
Nov-16-21 08:30AM	Tenax Therapeutics Reports Third Quarter 2021 Results and Provides Business Update (Business Wire)
Oct-06-21 08:30AM	Tenax Therapeutics Announces Clearance of the Investigational New Drug Application for Imatinib in Pulmonary Arterial Hypertension (PAH) (Business Wire)
Sep-28-21 08:30AM	Tenax Therapeutics to Present at the Benzinga Healthcare Small Cap Conference (Business Wire) +7.69%
Sep-20-21 10:43AM	TENX: Second Quarter Results (Zacks Small Cap Research) -6.57%
Sep-09-21 08:00AM	Tenax Therapeutics to Present at the H.C. Wainwright 23rd Annual Global Investment Conference (Business Wire)
Aug-17-21 08:00AM	Tenax Therapeutics Reports Second Quarter 2021 Results and Provides Business Update (Business Wire)
Aug-12-21 08:00AM	Tenax Announces New Publication Highlighting Novel Levosimendan Mechanism of Action in Pulmonary Hypertension Patients with Heart Failure and Preserved Ejection Fraction (PH-HFpEF) (Business Wire) -5.49%
Aug-05-21 08:00AM	Tenax Therapeutics Announced KOL Webinar on Levosimendan for Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF) (Business Wire) +5.73%
Jul-16-21 12:40PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX (Newsfile)
Jul-07-21 08:00AM	Tenax Therapeutics Announces CEO Transition and $10 Million PIPE Offering Priced At-the-Market under Nasdaq Rules (Business Wire)
Jun-14-21 04:25PM	Hedge Funds Are Selling Tenax Therapeutics Inc (TENX) (Insider Monkey)
Jun-10-21 08:30AM	Tenax Therapeutics Set to Join Russell Microcap® Index (Business Wire)
Jun-07-21 04:52PM	SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Shareholders of an Investigation Concerning Possible Breaches of Fiduciary Duty by Certain Officers and Directors of Tenax Therapeutics, Inc - TENX (Newsfile)
May-17-21 05:15PM	Tenax Therapeutics Reports First Quarter 2021 Results and Provides Business Update (Business Wire) -6.73%
Apr-14-21 07:45AM	TENX: HELP Results & New Asset to Boot (Zacks Small Cap Research)
Apr-09-21 11:38AM	Tenax Rises on Progress With Hypertension Treatment (TheStreet.com) +16.85%
08:00AM	Tenax Announces Publication Titled "Levosimendan Improves Hemodynamics and Exercise Tolerance in PH-HFpEF: Results of the Randomized Placebo-Controlled HELP Trial " (Business Wire)
Apr-07-21 04:45PM	Tenax Therapeutics Announces Continuation of Board Refreshment Program as Three Long-Serving Directors Volunteer to Not Stand for Re-Election at the Upcoming 2021 Annual Meeting of Stockholders (Business Wire)
Mar-31-21 04:45PM	Tenax Therapeutics Reports Fiscal Year 2020 Results and Provides Business Update (Business Wire)
Mar-04-21 08:30AM	Tenax Therapeutics to Present at the H.C. Wainwright Global Life Sciences Virtual Conference (Business Wire) -10.60%
Mar-02-21 08:15AM	Tenax Therapeutics, Inc. Expands Board of Directors (Business Wire)
Jan-20-21 10:30AM	TENX: Tenax Picks Up PH Precision Med (Zacks Small Cap Research)
07:45AM	Tenax Therapeutics Schedules Conference Call to Discuss Its Transformative Acquisition of PH Precision Med (Business Wire)
Jan-19-21 07:45AM	Tenax Therapeutics, Inc. Announces Transformative Acquisition of PH Precision Med (Business Wire) +32.58%
Dec-29-20 04:29PM	5 Top Stock Gainers for Tuesday: Snap, Barnes & Noble Education (TheStreet.com) +85.05%
10:12AM	Benzinga's Top Upgrades, Downgrades For December 29, 2020 (Benzinga)
Dec-03-20 07:47AM	TENX: FDA Meetings for Phase 3 Design (Zacks Small Cap Research) +17.14%
Nov-29-20 07:28PM	Is Tenax Therapeutics Inc (TENX) A Good Stock To Buy? (Insider Monkey)
Nov-16-20 04:45PM	Tenax Therapeutics Reports Third Quarter 2020 Results and Provides Business Update (Business Wire)
Nov-10-20 08:30AM	Tenax Therapeutics Announces Presentation of 24-Hour HELP Study Results at the American Heart Association Scientific Sessions 2020 (Business Wire)
Nov-06-20 08:30AM	Tenax Therapeutics to Host Virtual R&D Webinar with Scientific Experts Highlighting HELP Study Results (Business Wire) +7.80%
Oct-15-20 08:30AM	Tenax Therapeutics Gains North American Rights to Oral Levosimendan through Expanded License Agreement with Orion Corporation (Business Wire) +8.06%
Oct-02-20 08:30AM	Tenax Therapeutics Announces Late-Breaking Clinical Trial Presentation of Phase 2 HELP Study at Heart Failure Society of America (HFSA) Virtual Annual Scientific Meeting (Business Wire)
Sep-01-20 10:44AM	Tenax Therapeutics to Present at H.C. Wainwright 22nd Annual Global Investment Conference (Business Wire)
Aug-31-20 08:30AM	Tenax Announces Late-Breaking Results from the HELP Study Accepted for Presentation at the Heart Failure Society of America (HFSA) Annual Scientific Meeting (Business Wire)
Aug-28-20 10:54AM	TENX: Upcoming FDA Meetings for Ph3 Design (Zacks Small Cap Research)
Aug-17-20 08:00AM	Tenax Therapeutics Reports Second Quarter 2020 Results and Provides Business Update (Business Wire)
Jul-20-20 08:45AM	Tenax Therapeutics Expands Board of Directors with the Appointment of Two New Directors, Steven Boyd and Keith Maher, MD (Business Wire)
Jul-06-20 07:50PM	Tenax Therapeutics Announces $8.0 Million Registered Direct and PIPE Offerings Priced At-the-Market Under Nasdaq Rules (Business Wire)
Jun-03-20 09:41AM	Company News for June 3, 2020 (Zacks) -8.54%

Tenax Therapeutics, Inc. is a pharmaceutical company engaged in the development and commercialization of products for cardiovascular and pulmonary diseases. The company was founded on May 26, 1967 and is headquartered in Chapel Hill, NC.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

TENX

Tenax Therapeutics Inc

Upgrade your FINVIZ experience